Legislators considering changes to the 340B Drug Pricing Program have inquired about its size and scope. In a new Health Affairs blog post, experts from The Pew Charitable Trusts estimate the size of the program, as well as the impact that discounts have on prescription drug sales and manufacturer revenue. Their analysis finds that changes to the size of the 340B program would not affect overall drug spending and would alter only the distribution of discounts between manufacturers and hospitals.
Read the blog post.